Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Hyperlipoproteinemia Type II 1Glioma 1Glioblastoma 1

Interventions

Magnetic Resonance Spectroscopy 4pembrolizumab 2Radiotherapy 2Radiosurgery 2Positron Emission Tomography Computed Tomography 2Ipilimumab 2Cyclophosphamide 2tislelizumab 1teprotumumab 1pazopanib 1lenvatinib 1gallium citrate 1fludarabine phosphate 1fludarabine 1evolocumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1cabozantinib 1auricularum 1aldesleukin 1Spectrum Analysis 1Specimen Handling 1Pemetrexed 1Oxymorphone 1Oxycodone 1Nivolumab 1Morphine 1Levorphanol 1Lapatinib 1Hydromorphone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Neoplasm Metastasis × evolocumab × Clear all
NCT04862260 2026-03-19

Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma

CHU de Quebec-Universite Laval

Phase EARLY_PHASE1 Active not recruiting
3 enrolled
Gastrointestinal

Hyperlipoproteinemia Type II, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡